Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 4, 2010, Pages 811-826

  Faivre, Sandrine ^a   Sablin, Marie Paule ^a   Dreyer, Chantal ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Angiogenesis; Bevacizumab; Carcinoid; Everolimus; MTOR inhibitors; Sunitinib

Indexed keywords

ALPHA INTERFERON; AMG 479; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; DACARBAZINE; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; IMATINIB; LITHIUM; LX 1606; MK 0646; OCTREOTIDE; PASIREOTIDE; PEGINTERFERON ALPHA2B; PERTUZUMAB; PLACEBO; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; YTTRIUM 90;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CARCINOID SYNDROME; CLINICAL TRIAL; COLON CARCINOMA; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE TUMOR; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG CARCINOMA; LYMPHOCYTOPENIA; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCREAS ISLET CELL CARCINOMA; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 78649353727     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.09.006     Document Type: Review

References (74)

1. Halfdanarson T.R., Rabe K.G., Rubin J., et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008, 19:1727-1733.
2. Pape U.F., Bohmig M., Berndt U., et al. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann N Y Acad Sci 2004, 1014:222-233.
3. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005, 19:491-505.
4. Klöppel G., Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2005, 19:507-517.
5. Couvelard A., Deschamps L., Ravaud P., et al. Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol 2009, 22:273-281.
6. Couvelard A., Scoazec J.Y. A TNM classification for digestive endocrine tumors of midgut and hindgut: proposals from the European Neuroendocrine Tumor Society (ENETS). Ann Pathol 2007, 27:426-432.
7. Couvelard A., Hu J., Steers G., et al. Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology 2006, 131:1597-1610.
8. Rindi G., Klöppel G., Alhman H., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
9. Couvelard A., O'Toole D., Turley H., et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005, 17(92):94-101.
10. Ballian N., Loeffler A.G., Rajamanickam V., et al. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford) 2009, 11:422-428.
11. Moertel C.G., Kvols L.K., O'Connell M.J., et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991, 68:227-232.
12. Eriksson B., Annibale B., Bajetta E., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009, 90:214-219.
13. Yao K.A., Talamonti M.S., Nemcek A., et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001, 130:677-682.
14. Knigge U., Hansen C.P., Stadil F. Interventional treatment of neuroendocrine liver metastases. Surgeon 2008, 6:232-239.
15. Vilar E., Salazar R., Pérez-García J., et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007, 14:221-232.
16. Moertel C.G., Hanley J.A., Johnson L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980, 303:1189-1194.
17. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326:519-523.
18. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004, 22:4762-4771.
19. Heng P.N., Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999, 86:944-948.
20. McCollum A.D., Kulke M.H., Ryan D.P., et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004, 27:485-488.
21. Kumar U., Grant M. Somatostatin and somatostatin receptors. Results Probl Cell Differ 2010, 50:137-184.
22. Modlin I.M., Pavel M., Kidd M., et al. Review article: somatostatin analogs in the treatment of gastro-entero-pancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther 2010, 31:169-188.
23. Oberg K., Kvols L., Caplin M., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15:966-973.
24. Msaouel P., Galanis E., Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs 2009, 18:1297-1316.
25. Rinke A., Muller H.H., Schade-Brittinger C., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27:4656-4663.
26. Fazio N., de Braud F., Delle Fave G., et al. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. Ann Oncol 2007, 18:13-19.
27. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005, 23:2754-2762.
28. Valkema R., Pauwels S., Kvols L.K., et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006, 36:147-156.
29. Waldherr C., Pless M., Maecke H.R., et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001, 12:941-945.
30. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002, 43:610-616.
31. Virgolini I., Britton K., Buscombe J., et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002, 32:148-155.
32. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26:2124-2130.
33. Casanovas O., Hicklin D.J., Bergers G., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
34. Inoue M., Hager J.H., Ferrara N., et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002, 1:193-202.
35. Fjallskog M.L., Lejonklou M.H., Oberg K.E., et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003, 9:1469-1473.
36. Fjallskog M.L., Hessman O., Eriksson B., et al. Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 2007, 46:741-746.
37. Faivre S., Demetri G., Sargent W., et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745.
38. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
39. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005, 23:939-952.
40. Yao VJ, Sennino B, Davis RB, et al. Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models. In: Programs and abstract of the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Prague: 2006 0 AD/11/7.
41. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
42. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403-3410.
43. Raymond E., Faivre S., Hammel P., et al. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol 2009, 4:253-254.
44. Zhang J., Jia Z., Li Q., et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007, 109:1478-1486.
45. Yao J.C., Phan A., Hoff P.M., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26:1316-1323.
46. Missiaglia E., Dalai I., Barbi S., et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010, 28:245-255.
47. Capdevila J., Salazar R. Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Target Oncol 2009, 4:287-296.
48. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
49. Vignot S., Faivre S., Aguirre D., et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16:525-537.
50. Zhang H., Cicchetti G., Onda H., et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003, 112:1223-1233.
51. Zhang H., Bajraszewski N., Wu E., et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007, 117:730-738.
52. Chung D.C., Brown S.B., Graeme-Cook F., et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res 1998, 58:3706-3711.
53. Rigaud G., Missiaglia E., Moore P.S., et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: Identification of two molecular subgroups with clinical implications. Cancer Res 2001, 61:285-292.
54. Perren A., Komminoth P., Saremaslani P., et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000, 157:1097-1103.
55. Kaper F., Dornhoefer N., Giaccia A. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res 2006, 66:1561-1569.
56. Guo S.S., Wu X., Shimoide A.T., et al. Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J Endocrinol 2003, 179:73-79.
57. Grozinsky-Glasberg S., Franchi G., Teng M., et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008, 87:168-181.
58. Zitzmann K., De Toni E.N., Brand S., et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007, 85:54-60.
59. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-2347.
60. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006, 95:1148-1154.
61. O'Donnell A., Faivre S., Burris H.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26:1588-1595.
62. Yao J.C., Phan A.T., Chang D.Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 2008, 26:4311-4318.
63. Höpfner M., Baradari V., Huether A., et al. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 2006, 13:135-149.
64. Strosberg J.R., Kvols L.K. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007, 16:219-224.
65. Arnold R., Rinke A., Schmidt C.H., et al. Endocrine tumours of the gastrointestinal tract: Chemotherapy. Best Pract Res Clin Gastroenterol 2005, 19:649-656.
66. Ekeblad S., Sundin A., Janson E.T., et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007, 13:2986-2991.
67. Maire F., Hammel P., Faivre S., et al. Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology 2009, 90:67-72.
68. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24:401-406.
69. Schwarzberg A.B., Stover E.H., Sengupta T., et al. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest 2007, 25:249-255.
70. Kulke MH, Frauenhoffer S, Hooshmand SM, et al. Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET) [abstract 4505]. In programs and abstracts of the 2007 ASCO Annual Meeting. Chicago (IL), June 1-5, 2007. p. S18.
71. Bracht L.K., Wen P., Meyerhardt J.A., et al. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol 2008, 26:4843-4844.
72. Kulke M.H., Hornick J.L., Frauenhoffer C., et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009, 15:338-345.
73. Gounaris I., Rahamim J., Shivasankar S., et al. Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma. Anticancer Drugs 2007, 18:1227-1230.
74. Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?. Curr Opin Oncol 2010, 22:381-386.